ObGyn physicians routinely reference clinical practice guidelines, landmark studies, therapeutic approaches, and risk assessment tools that guide patient care across obstetrics, gynecology, reproductive medicine, menopause, and preventive health. The following 10-item framework reflects widely used sources that inform ObGyn care.

1. American Society for Colposcopy and Cervical Pathology Risk-Based Management Guidelines — The American Society for Colposcopy and Cervical Pathology developed risk-based guidelines for the management of abnormal cervical cancer screening results. The framework uses current and prior human papillomavirus and cytology test results to estimate the risk of cervical precancer and support risk-based clinical management decisions.

2. American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin: Gestational Hypertension and Preeclampsia — ACOG provides guidance on the diagnosis and management of gestational hypertension and preeclampsia. The bulletin addresses conditions that are associated with substantial maternal and perinatal morbidity and mortality and remain a significant focus of obstetric care.

3. Society for Maternal-Fetal Medicine Consult Series #52: Fetal Growth Restriction Guidance — The Society for Maternal-Fetal Medicine outlines an evidence-based, standardized approach to the prenatal diagnosis and management of fetal growth restriction. The guidance defines diagnostic criteria for fetal growth restriction and includes recommendations regarding ultrasound evaluation, umbilical artery Doppler assessment, fetal surveillance, and timing of delivery.

4. American Society for Reproductive Medicine Committee Opinion: Fertility Evaluation of Infertile Women — The American Society for Reproductive Medicine outlines an approach to infertility evaluation that focuses on identifying common causes through appropriate diagnostic testing. The guidance includes recommendations regarding the timing of evaluation, circumstances that warrant earlier assessment, and the concurrent evaluation of both partners when a male factor may contribute to infertility.

5. Chronic Hypertension and Pregnancy Trial — In the Chronic Hypertension and Pregnancy trial involving pregnant patients with mild chronic hypertension, a strategy of targeting blood pressure below 140/90 mm Hg was associated with a lower incidence of the study’s primary composite outcome compared with reserving treatment for severe hypertension. Researchers found no increase in small-for-gestational-age birth weight with active treatment.

6. ARRIVE Trial — In the ARRIVE trial involving low-risknulliparous patients, induction of labor at 39 weeks was associated with a lower rate of cesarean delivery compared with expectant management. Researchers found no statistically significant difference in the study’s composite adverse perinatal outcome between groups.

7. Women’s Health Initiative Hormone Therapy Trials — The Women’s Health Initiative evaluated the health effects of menopausal hormone therapy in postmenopausal women. Findings from the randomized trials informed understanding of hormone therapy use and its association with menopausal symptoms, cardiovascular disease, cognition, bone health, and other long-term outcomes.

8. Long-Acting Reversible Contraception — ACOG outlines evidence-based considerations for the use of contraceptive implants and intrauterine devices. The bulletin reviews candidate selection and key aspects of incorporating long-acting reversible contraception into clinical practice.

9. The Menopause Society Hormone Therapy Position Statement — The Menopause Society provides guidance on the use of hormone therapy in menopause, including considerations related to symptom treatment and bone health. The statement discusses clinical factors that may affect treatment decisions and supports tailoring therapy to a patient’s circumstances with regular reassessment over time.

10. TyrerCuzick Breast Cancer Risk Model — The TyrerCuzick model, also known as the International Breast Cancer Intervention Study (IBIS) Risk Evaluation Tool, estimates a woman’s likelihood of developing breast cancer by incorporating family history, genetic predisposition, reproductive factors, and benign breast disease history.

Sources: The New England Journal of Medicine, Society for Maternal-Fetal Medicine, American College of Obstetricians and Gynecologists, Journal of Lower Genital Tract Disease, IBIS Risk Evaluator Software, American Society for Reproductive Medicine, Menopause, JAMA